CTIC | CTI BioPharma Corp. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	9.09 - 9.10
52 Week Range	4.01 - 9.10
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	5,558,437
Average Volume	5,661,603
Shares Outstanding	131,880,000
Market Cap	1,199,448,600
Sector	Healthcare
Industry	Biotechnology
IPO Date	1997-03-21

Valuation
Profitability
Growth
Health
P/E Ratio	-16.84
Forward P/E Ratio	N/A
EPS	-0.54
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	127
Country	USA
Website	CTIC

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

CTIC's peers: ATNM, CVM, RIGL

*Chart delayed

Analyzing fundamentals for CTIC we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see CTIC Fundamentals page.

Watching at CTIC technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on CTIC Technicals page.